SA1211 injection safety and dosing in people with chronic hepatitis B and healthy volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA1211 Injection in Healthy Participants and Participants With Chronic Hepatitis B
Run by Suzhou Siran Biotechnology Co.,Ltd. · NCT07275918 · Data updated 2026-11-12
This trial will test whether one or multiple under-the-skin injections of SA1211 are safe, trigger immune responses, and show early signs of benefit in adults with chronic hepatitis B and in healthy volunteers.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Suzhou Siran Biotechnology Co.,Ltd. Industry-sponsored |
| Locations | 1 site (Changchun, Jilin) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | March 30, 2027 |
| Study ends | March 30, 2027 |
| Registry record updated | December 10, 2025 |
| Trial ID | NCT07275918 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with chronic hepatitis B who meet the trial's age (18–65), BMI (18–32 kg/m²), and screening lab criteria, as well as healthy volunteers aged 18–55 for the single-dose part.
✕Probably not a fit
People with advanced or decompensated liver disease, unstable medical conditions, or who do not meet the age, BMI, or screening laboratory criteria are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1, first-in-human trial has two parts: a single-dose part in healthy volunteers (Part A) and a multiple-dose part in adults with chronic hepatitis B (Part B). Participants receive subcutaneous injections of SA1211 or placebo and undergo safety monitoring, laboratory tests, immunogenicity assays, and pharmacokinetic blood sampling. The study will characterize tolerability, immune responses, and drug levels over time and look for preliminary antiviral or clinical signals in the CHB group. Findings will guide dosing and design of later-stage trials.
Why it matters
Potential benefit: If successful, SA1211 could help people with chronic hepatitis B by boosting immune responses and reducing viral activity.
How similar studies have gone: Other early-phase immune-based approaches for chronic hepatitis B have shown immunogenicity in small trials but only occasional antiviral control, so this approach remains experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Able to correctly understand and sign the informed consent form in writing. 2. Male or female participants. * For healthy participants: aged 18-55 years old (inclusive of the cut-off values). * For participants with chronic hepatitis B (CHB): aged 18-65 years old (inclusive of the cut-off values). 3. Body Mass Index (BMI) meets the following requirements. * For healthy participants: within the range of 18-28 kg/m² (inclusive of the cut-off values). * For participants with chronic hepatitis B (CHB): within the range of 18-32 kg/m² (inclusive of the cut-off values). 4. During the screening period, the results of the following examinations are either normal or abnormal but not clinically insignificant: \- Clinical laboratory tests: complete blood count, blood biochemistry, coagulation function, urine routine. Thyroid function test. 12-lead electrocardiogram (ECG). Abdominal ultrasound. Posteroanterior chest X-ray. 5. For participants with chronic hepatitis B (CHB): documented hepatitis B virus (HBV) infection for at least 6 months before screening, with positive hepatitis B surface antigen (HBsAg) and/or positive HBV deoxyribonucleic acid (HBV DNA). 6. For female participants of childbearing potential: must not be pregnant or lactating, and agree to use effective contraception during the study period. 7. For male participants of childbearing potential: agree to use effective contraception during the study period to ensure effective contraception for their sexual partners. Exclusion Criteria: 1. Participants with concurrent hepatitis C virus (HCV), human immunodeficiency virus (HIV) or syphilis infection; or those previously diagnosed with hepatitis A, D, or E who have not been cured. 2. Participants with severe diseases, including but not limited to diseases of the nervous, cardiovascular, hematological and lymphatic, immune, renal, hepatic, thyroid, gastrointestinal, respiratory, metabolic, and skeletal systems, as well as a history of malignant tumors. 3. Participants with severe mental illness or uncontrolled mental disorders, including but not limited to schizophrenia, bipolar disorder, or depression. 4. Participants with a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening, who are deemed unsuitable for the study by the investigator. 5. Participants who have undergone major surgery within 6 months before screening, or plan to undergo surgery during the study period. 6. Participants with severe infection or trauma within 4 weeks before screening. 7. Participants with a severe allergic constitution, or a confirmed allergy to this product or its formulation components. 8. Participants who smoked more than 5 cigarettes per day or the equivalent amount of tobacco within 3 months before screening. 9. Participants deemed unsuitable for the trial by the investigator due to other factors.
Where it's running
-
The First Hospital of Jilin University
Changchun, Jilin, China Recruiting
Study contacts
- Study coordinator: Feifei Zhao
- Email: zhaofeifei@siranbio.com
- Phone: +86 0512-65295926
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of functional cure on patient-reported outcomes in chronic hepatitis B
This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.
-
Sequential combination therapy for functional cure of chronic hepatitis B
This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.
-
Combination therapy for functional cure in chronic hepatitis B
This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.
-
GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B
A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.
-
AHB-137 injection in people with chronic hepatitis B
This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.
-
AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function
This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.